Nottingham Advisors Inc. Continues to Hold Holdings in Amgen Inc. (AMGN)
Nottingham Advisors Inc. continued to hold its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,320 shares of the medical research company’s stock at the end of the second quarter. Nottingham Advisors Inc.’s holdings in Amgen were worth $227,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in AMGN. Waldron LP acquired a new position in Amgen during the first quarter valued at approximately $444,000. Meritage Portfolio Management raised its position in Amgen by 0.5% during the first quarter. Meritage Portfolio Management now owns 45,730 shares of the medical research company’s stock valued at $7,503,000 after purchasing an additional 230 shares in the last quarter. NBT Bank N A NY raised its position in Amgen by 19.9% during the first quarter. NBT Bank N A NY now owns 5,565 shares of the medical research company’s stock valued at $913,000 after purchasing an additional 925 shares in the last quarter. Mycio Wealth Partners LLC raised its position in Amgen by 6.9% during the first quarter. Mycio Wealth Partners LLC now owns 5,594 shares of the medical research company’s stock valued at $918,000 after purchasing an additional 363 shares in the last quarter. Finally, Dubuque Bank & Trust Co. raised its position in Amgen by 8.6% during the first quarter. Dubuque Bank & Trust Co. now owns 78,713 shares of the medical research company’s stock valued at $12,914,000 after purchasing an additional 6,228 shares in the last quarter. Institutional investors and hedge funds own 78.10% of the company’s stock.
Shares of Amgen Inc. (NASDAQ AMGN) traded down 0.55% during mid-day trading on Friday, reaching $185.82. 2,239,269 shares of the company’s stock were exchanged. The stock has a market cap of $135.59 billion, a PE ratio of 16.92 and a beta of 1.36. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The company has a 50 day moving average price of $181.33 and a 200-day moving average price of $170.23. Amgen also was the recipient of some unusual options trading activity on Thursday. Stock traders purchased 9,350 put options on the company. This represents an increase of approximately 239% compared to the typical daily volume of 2,758 put options.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the company earned $2.84 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, analysts predict that Amgen Inc. will post $12.58 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date was Tuesday, August 15th. Amgen’s payout ratio is 41.93%.
AMGN has been the subject of several research analyst reports. Jefferies Group LLC restated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research report on Tuesday, July 11th. Mizuho reiterated a “buy” rating and set a $195.00 price target on shares of Amgen in a report on Sunday, July 9th. ValuEngine upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Tuesday, June 13th. Finally, Cann reiterated a “buy” rating and set a $203.00 price target (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Ten equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $189.99.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.